GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy

BACKGROUND: In China, platinum-based doublet chemotherapy is the standard treatment for patients who have unresectable stage III non-small cell lung cancer (NSCLC), administered with radiotherapy on either a concurrent or sequential basis. However, NSCLC patients who undergo this treatment can expec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qing, Chen, Ming, Wu, Gang, Chang, Jian-Hua, Jiang, Ou, Cui, Jiu-Wei, Han, Guang, Lin, Qin, Fang, Jian, Chen, Gong-Yan, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653154/
https://www.ncbi.nlm.nih.gov/pubmed/33209620
http://dx.doi.org/10.21037/tlcr-20-608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653154/
https://www.ncbi.nlm.nih.gov/pubmed/33209620
http://dx.doi.org/10.21037/tlcr-20-608

Ejemplares similares